The US Pharmacopeia (USP) has proposed a revision to General Chapter <660> Container—Glass, which provides specifications for ...

Public markets are showing early signs of reopening, as Q4 2025 saw a 157% increase in IPO deal volume compared to Q4 2024.

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Agenus has completed a $141m strategic collaboration with Zydus Lifesciences to accelerate the global development and ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

While the FDA came out on top over the EMA in terms of approvals, both agencies greenlighted fewer new drugs than in 2024.

The Billion Cell Atlas, backed by Eli Lilly, MSD and AstraZeneca, maps mechanisms to support informed drug discovery and ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.